COMMUNIQUÉS West-GlobeNewswire

-
Cutera, Inc. to Announce Fourth Quarter and Full-Year 2018 Results
30/01/2019 -
Assure Holdings Continues Expansion with New Partnership in Louisiana
30/01/2019 -
Kane Biotech Expands Previously-Announced Single Largest Order of bluestem™ Products
30/01/2019 -
IntelGenx Facility Undergoes U.S. FDA Pre-Approval Inspection Related to RIZAPORT® NDA
30/01/2019 -
Neos Therapeutics Announces Appointment of James Robinson to Board of Directors
30/01/2019 -
AMAG Pharmaceuticals to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call and Webcast on Thursday, February 7, 2019 at 8:00 a.m. ET
30/01/2019 -
CytomX Therapeutics to Host Research and Development Day on February 26, 2019
30/01/2019 -
BioTime Inc. Affiliate Company OncoCyte Corporation Reports Successful Results With DetermaVu™ Diagnostic Test for Lung Cancer
30/01/2019 -
Aduro Biotech Announces Strategic Reset
30/01/2019 -
Le Dr. Eric Simpson présentera les résultats obtenus avec bermekimab dans le traitement de la dermatite atopique lors de l’Assemblée annuelle 2019 de l’American Academy of Dermatology (AAD)
30/01/2019 -
TG Therapeutics, Inc. Announces Publication of Clinical Data from the Phase I Triple Therapy Combination Trial of Ublituximab, Umbralisib, and Ibrutinib in The Lancet Haematology
30/01/2019 -
Stemline Therapeutics Announces Validation of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA)
30/01/2019 -
Aino Health AB (publ): Aino Health signs partnership agreement with Uudenmaan Työterveys, (Nylands Arbetshälsa)
30/01/2019 -
Kamada Appoints Senior Biopharmaceutical Executive Michal Ayalon, Ph.D., as Vice President of Research and Development
30/01/2019 -
Mithra Announces Positive Top-line Results of Estelle® Phase III Oral Contraceptive Study in U.S/Canada
30/01/2019 -
Emerald Health Therapeutics Announces Discharge of Litigation
30/01/2019 -
Eyenovia Announces Positive Results in the MicroStat MIST-1 Phase III Registration Study for Mydriasis
30/01/2019 -
Trevena Announces $10 Million Registered Direct Offering of Common Stock
30/01/2019 -
Axsome Therapeutics Initiates Phase 2 Trial of AXS-12 in Narcolepsy
30/01/2019
Pages